Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director | May 18, 2026 | May 19, 2026 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 19, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.
NeuroPace Inc
Report date June 19, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,039 |
Reported balance
After 2026-06-19 transaction · row 1
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 989 · Balance 23,039 F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Roivant Sciences Ltd.
Report date February 20, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 162,306 |
Reported balance
After 2025-02-20 transaction · row 1
1 source rowRow 1 · 2025-02-20 · Tax withholding · Disposed 958 · Balance 162,306 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 22, 2026 20:32 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 989 | $15.63 | $15,458.07 |
DisclosureSEC source: 0001856296-26-000007 · wk-form4_1782160357.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,039 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 5,368 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001856296-26-000005 · wk-form4_1780693812.xml · derivative · entry 2 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 Underlying: Common Stock · 5,368 shares Expires 2036-06-04 F2 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001856296-26-000005 · wk-form4_1780693812.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,050 F1 · shares: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:42 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,153 | $13.00 | $14,989.00 |
DisclosureSEC source: 0001856296-26-000003 · wk-form4_1774298557.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,160 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:15 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 904 | $16.59 | $14,997.36 |
DisclosureSEC source: 0001856296-25-000005 · form4-12232025_041221.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,007 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 23:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,509 | $9.94 | $14,999.46 |
DisclosureSEC source: 0001856296-25-000003 · form4-09222025_070904.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,103 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,440 | $10.41 | $14,990.40 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 9 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,594 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 21:26 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (right to buy) · Derivative | 8,745 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001415889-25-016328 · form4-06092025_050610.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,745 Underlying: Common Stock · 8,745 shares Expires 2035-06-05 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,247 | $12.02 | $14,988.94 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 8 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,154 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 958 | $10.72 | $10,269.76 |
DisclosureSEC source: 0001140361-25-005719 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,306 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-25-005053 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,500 Underlying: Common Stock · 187,500 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 227,500 | $10.43 | $2,372,825.00 |
DisclosureSEC source: 0001140361-25-005053 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,264 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 187,500 | $3.85 | $721,875.00 |
DisclosureSEC source: 0001140361-25-005053 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:04 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,057 | $11.15 | $11,785.55 |
DisclosureSEC source: 0001140361-25-001663 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,264 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 21, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,300 | $11.53 | $14,989.00 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 7 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,907 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 20, 2024 Filed Dec 27, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 3,087 | $11.57 | $35,716.59 |
DisclosureSEC source: 0001140361-24-050459 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,321 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| November 20, 2024 Filed Nov 23, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 958 | $11.49 | $11,007.42 |
DisclosureSEC source: 0001140361-24-047698 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,408 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| October 20, 2024 Filed Oct 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 956 | $11.92 | $11,395.52 |
DisclosureSEC source: 0001140361-24-043961 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,366 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 30, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,152 | $6.97 | $14,999.44 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 6 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,607 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-24-041789 · form4.xml · derivative · entry 4 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 250,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 250,000 | $11.89 | $2,972,500.00 |
DisclosureSEC source: 0001140361-24-041789 · form4.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,322 F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 250,000 | $3.85 | $962,500.00 |
DisclosureSEC source: 0001140361-24-041789 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 3,087 | $11.97 | $36,951.39 |
DisclosureSEC source: 0001140361-24-041789 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,322 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 958 | $11.48 | $10,997.84 |
DisclosureSEC source: 0001140361-24-038307 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,409 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| July 20, 2024 Filed Jul 26, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 958 | $11.00 | $10,538.00 |
DisclosureSEC source: 0001140361-24-034283 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,367 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stoch Purchase Plan. Read SEC document |
| June 28, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,984 | $7.56 | $14,999.04 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 5 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,455 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 3,087 | $10.80 | $33,339.60 |
DisclosureSEC source: 0001140361-24-031175 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,123 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:17 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 17,774 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016361 · form4-06112024_080649.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,774 Underlying: Common Stock · 17,774 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 23, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,363 | $11.37 | $15,497.31 |
DisclosureSEC source: 0001140361-24-027207 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,210 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 22, 2024 Filed Apr 25, 2024 01:12 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 230,548 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001140361-24-021818 · form4.xml · derivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,548 Underlying: Common Shares · 230,548 shares Expires 2034-04-21 F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2024. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| April 22, 2024 Filed Apr 25, 2024 01:12 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 38,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-021818 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,573 F1 · shares: Reflects an award of 38,685 restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2024. 1/4 of the RSUs service-vest on the date thirteen (13) months from the vesting commencement date; and the balance of the RSUs service-vest in series of twelve (12) successive equal quarterly installments measured from the date thirteen (13) months from the vesting commencement date, subject to the reporting person's Continuous Service through the applicable vesting date. Read SEC document |
| April 20, 2024 Filed Apr 24, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 9,881 | $10.46 | $103,355.26 |
DisclosureSEC source: 0001140361-24-021493 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,888 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 29, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,136 | $13.20 | $14,995.20 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 4 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,471 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| March 20, 2024 Filed Mar 23, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,506 | $10.01 | $15,075.06 |
DisclosureSEC source: 0001140361-24-014895 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,769 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 02:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,508 | $11.54 | $17,402.32 |
DisclosureSEC source: 0001140361-24-009098 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,275 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,506 | $10.35 | $15,587.10 |
DisclosureSEC source: 0001140361-24-003549 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,783 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,454 | $10.31 | $14,990.74 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 3 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,335 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 1,894 | $11.50 | $21,781.00 |
DisclosureSEC source: 0001140361-23-060291 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,126 Underlying: Common Shares · 13 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · derivative.exercise_price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · derivative.exercise_date: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F3 · derivative.underlying_shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 6 | $11.58 | $69.48 |
DisclosureSEC source: 0001140361-23-060291 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,289 F2 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. Read SEC document |
| December 27, 2023 Filed Dec 30, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 13 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-060291 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023. Read SEC document |
| December 20, 2023 Filed Dec 23, 2023 00:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,364 | $9.96 | $13,585.44 |
DisclosureSEC source: 0001140361-23-059239 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,282 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| November 22, 2023 Filed Nov 28, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,415 | $8.68 | $12,282.20 |
DisclosureSEC source: 0001140361-23-054758 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,646 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| October 24, 2023 Filed Oct 27, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,563 | $8.99 | $14,051.37 |
DisclosureSEC source: 0001140361-23-049765 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,061 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,541 | $9.73 | $14,993.93 |
DisclosureSEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,881 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 28, 2023 Filed Sep 30, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 92 | $12.67 | $1,165.64 |
DisclosureSEC source: 0001140361-23-046106 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,624 F2 · kind: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's "sell to cover" policy and does not represent a discretionary sale by the reporting person. F3 · price: The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $13.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 27, 2023 Filed Sep 30, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 1,894 | $11.50 | $21,781.00 |
DisclosureSEC source: 0001140361-23-046106 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,020 Underlying: Common Shares · 169 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F4 · derivative.exercise_price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F4 · shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F4 · price: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F4 · derivative.exercise_date: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F4 · derivative.underlying_shares: This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. Read SEC document |
| September 27, 2023 Filed Sep 30, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-046106 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On September 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 169 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023. Read SEC document |
| September 22, 2023 Filed Sep 27, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,403 | $10.19 | $14,296.57 |
DisclosureSEC source: 0001140361-23-045330 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,547 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 99,350 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001140361-23-043730 · form4.xml · derivative · entry 3 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 99,350 shares Expires 2027-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 99,350 | $12.18 | $1,210,083.00 |
DisclosureSEC source: 0001140361-23-043730 · form4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,950 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.